Similar results have been reported by several other groups ; Busciglio et al. 1993; Haass and Selkoe 1993) . Thus there is a normal metabolic pathway that produces and releases significant amounts of a soluble -v4 kD /3APP derivative essentially identical to the A/3 deposited as amyloid in Alzheimer's disease.
In rare families, AD is inherited as an autosomal dominant trait. Strong evidence that amyloid deposition plays a critical role in the development of AD has come from the identification of familial AD (FAD) kindreds in which the AD phenotype cosegragates with mutations in the $APP gene. Three of the FADlinked fAPP mutations convert the valine located three residues COOH to Af43 (va1717 in /3APP770), to isoleucine (QI), phenylalanine (JF), or glycine (aG) Yoshioka et al. 1991) . A fourth double mutation (aNL) alters the lysine-methionine located immediately NH2 to A/31 (lys670-met671 in /3APP770) to asparagine-leucine (Mullan 1992) . The location of these mutations in close proximity to A/3 immediately suggests that they may cause AD by altering /3APP processing in a way that is amyloidogenic.
To determine if these mutations do, in fact, alter A/3 production in the pathway described above, we stably transfected human neuroblastoma (M 17) cells and compared lines expressing normal or mutant $APP 695 (Cai et al. 1993 ). After continuous metabolic labeling for 8 hr, cells expressing mutant /3APPaNL showed a 5-fold increase in the relative amount of the -11.4 kD A/3-bearing COOH-terminal /3APP derivative, and they released 6-fold more 4 kD A/3 into the medium. Similar results have been reported by Citron et al. (1992) . These observations (i) provide strong evidence that this mutant /3APP causes AD because it undergoes altered processing that releases increased amounts of A/3, and
(ii) indicate that the pathway producing A/3 in cultured cells is highly relevant to AD. More generally, the linkage of FAD to a /3APPaNL mutation demonstrated to increase A/3 production greatly strengthens the hypothesis that amyloid deposition plays a central role in the development of all forms of AD. If amyloid deposition is invariably pivotal in the development of AD, then both the /3APPz1NL and the /3APP4717 mutations (QI, 1F, and zG) should alter /3APP processing in a way that is amyloidogenic. Our data showed, however, that transfected M 17 cells expressing /3APP695dI do not release increased amounts of A/3 (Cai et al. 1993 ). To account for this observation, we proposed that the FAD-linked 4717 mutations on the carboxyl side of A/3 (QI, zlF, zG) shift cleavage to favor generation of longer A/3s such as A/31-42 or All-43. Since these longer A/3s form amyloid fibrils more rapidly than All-40 (Hilbich et al. 1991; Burdick et al. 1992 ; Jarrett and Lansbury 1993; , shifting the site of cleavage could result in amyloid deposition without increasing the overall amount of A/3 produced.
To test this hypothesis, we used two methods to compare the effect of the fAPP717 mutations on the relative amounts of A/31-40 and All-42, 43 secreted by appropriately transfected M 17 cells (Suzuki et al. 1994 ). In the first method, All-40 and A/31-42, 43 were distinguished and quantitated by isolating metabolically labeled A/3 from conditioned media, digesting the AR with cyanogen bromide to release radiolabeled carboxyl-terminal peptides (Af36-40 or Af36-42, 43), and analyzing the carboxyl-terminal peptides by RPLC using a C4 column. In the second method, highly sensitive sandwich ELISAs that discriminate synthetic A/31-40 from A/31-42, 43 were employed. With both methods, we invariably observed the relative amount of A/31-42, 43 produced by fAPP717 mutants (4I or 4F) to be 1.5-2.0-times that produced by control /3APPs.
Quantitation of the sandwich ELISA data showed the percentages of All-42, 43 secreted by cells expressing wild type fAPP695, fAPP6954I, and /3APP6954F to be 17.5±0.5%, 25.7±0.5% (p<0.002) and 31.4±0.6% (p<0.0002), respectively.
Although the /3APP717-induced increase in long A/3 production is relatively modest, in vitro studies by Lansbury and his colleagues (Jarrett and Lansbury 1993; indicate that the impact of this shift on amyloid deposition could be substantial.
These studies indicate that AR aggregation into amyloid is a nucleation dependent polymerization ( With the discovery that A/3 is produced and released by normal processing of the /3APP, it is clear that Ap is an unusual secreted protein released from within the /3APP through cleavage by /3 and y secretase (Fig. 1) . Thus in AD, as is the other known amyloidoses, amyloid deposition is a process in which a secreted protein forms insoluble fibrils that deposit extracellularly.
The rate at which amyloid accumulates in the brain will depend on the four processes illustrated schematically in Fig. 2: (i) the rate at which the various A/3 peptides are secreted, (ii) the rate at which these secreted A/3 peptides are removed (together these two rates determine A/3 concentration), (iii) the rate at which A/3 fibrils form at any prevailing concentration of A/3, and (iv) the rate at which deposited amyloid fibrils are removed. Recently it has become apparent that a number of extracellular proteins can form complexes with A/3 (Ghiso et al. 1993; Schwarzmann et al. 1993 ). These A/3-binding proteins are potenitally very important not only because they will influence the fraction of A/3 that is free but also because they may substantially influence removal of secreted A/3, the rate at which amyloid fibrils form, or the rate at which amyloid fibrils are removed (Fig. 2) .
In the brains of all patients with AD, substantial amounts of amyloid are deposited extracellularly.
Thus it is reasonable to propose that amyloid deposition may be an essential element in a serial cascade of age-related pathologic changes that ultimately produces the dementia observed in AD. The FAD-linked /3APPaNL and /3APP 717 mutations provide strong support for this hypothesis, because each of these genetic changes reliably produces AD, and each enhances amyloidogenesis by increasing secretion of total A/3 or A/31-42 (Fig. 2) . It is likely that trisomy 21 also causes AD by enhancing amyloid deposition since patients with trisomy 21 have an extra copy of the /3APP gene and show increased expression of /3APP (Tanzi et al. 1987 ) which is normally processed to release A/3.
Recently it has become evident that there are many individuals with extensive cerebral A/3 deposition who are not demented. Given the strong genetic evidence favoring the amyloid deposition hypothesis, it is reasonable to propose that these are at risk individuals who have not yet progressed to dementia either because amyloid deposition is recent or because genetic or environmental factors involved in the progression from amyloid deposition to dementia are not favorable. At autopsy, there is some A/3 deposited in the brain of almost everyone Note that A/3 is produced through cleavage by proteases referred to as $ and y secretase and that p3, a smaller peptide not discussed in the text, is produced through cleavage by a and y secretase.
The approximate molecular weight of various carboxyl-terminal fragments produced during $APP processing is shown in kD.
over 65 indicating that the conditions needed for minimal amyloid deposition are commonplace in the elderly human brain. The realization that the incidence of AD may be as high as 50% in individuals over the age of 85 indicates that with sufficient aging an extraordinary fraction of the population may deposit enough amyloid to produce dementia. Thus it appears that there is a strong tendency toward amyloid deposition in the aging human brain and the relatively subtle differences in the factors that promote amyloid deposition may decide whether or not substantial amounts of amyloid are deposited. Since there appears to be considerable interindividual variation in the pathology that is provoked by amyloid deposition, the challenge for those favoring the amyloid deposition hypothesis is to demonstrate that all AD can be accounted for in terms of factors that influence amyloid deposition or pathology that is provoked by amyloid deposition. There is very little information on many of the processes likely to influence the amount of amyloid that accumulates in the aging human brain. Thus the relative importance of the various processes illustrated is unknown.
